Cargando…

Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer

BACKGROUND: Gastric cancer (GC) is one of the most common malignant tumors worldwide, and we hope to identify an economical but practical prognostic indicator. It has been reported that inflammatory indicators and tumor markers are associated with GC progression and are widely used to predict progno...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Liang, Jiang, Runben, Chen, Wanjing, Liu, Yanwei, Wang, Gui, Gong, Xin, Wang, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938584/
https://www.ncbi.nlm.nih.gov/pubmed/36803398
http://dx.doi.org/10.1186/s12957-023-02926-w
_version_ 1784890663351877632
author Yu, Liang
Jiang, Runben
Chen, Wanjing
Liu, Yanwei
Wang, Gui
Gong, Xin
Wang, Yong
author_facet Yu, Liang
Jiang, Runben
Chen, Wanjing
Liu, Yanwei
Wang, Gui
Gong, Xin
Wang, Yong
author_sort Yu, Liang
collection PubMed
description BACKGROUND: Gastric cancer (GC) is one of the most common malignant tumors worldwide, and we hope to identify an economical but practical prognostic indicator. It has been reported that inflammatory indicators and tumor markers are associated with GC progression and are widely used to predict prognosis. However, existing prognostic models do not comprehensively analyze these predictors. METHODS: This study retrospectively reviewed 893 consecutive patients who underwent curative gastrectomy from January 1, 2012, to December 31, 2015, in the Second Hospital of Anhui Medical University. Prognostic factors predicting overall survival (OS) were analyzed using univariate and multivariate Cox regression analyses. Nomograms including independent prognostic factors were plotted for predicting survival. RESULTS: Ultimately, 425 patients were enrolled in this study. Multivariate analyses demonstrated that the neutrophil-to-lymphocyte ratio (NLR, total neutrophil count/lymphocyte count × 100%) and CA19-9 were independent prognostic factors for OS (p=0.001, p=0.016). The NLR-CA19-9 score (NCS) is constructed as the combination of the NLR and CA19-9. We defined NLR<2.46 and CA19-9≤37 U/ml as an NCS of 0, NLR≥2.46 or CA19-9>37 U/ml as an NCS 1, and NLR≥2.46 and CA19-9>37 U/ml as an NCS of 2. The results showed that higher NCS was significantly associated with worse clinicopathological characteristics and OS (p<0.05). Multivariate analyses revealed that the NCS was an independent prognostic factor for OS (NCS1: p<0.001, HR=3.172, 95% CI=2.120–4.745; NCS2: p<0.001, HR=3.052, 95% CI=1.928–4.832). Compared with traditional predictive indices, the NCS had the highest AUC for a 12-month survival, a 36-month survival, a 60-month survival, and OS (AUC= 0.654, 0.730, 0.811, 0.803, respectively). The nomogram had a higher Harrell’s C-index than the TNM stage alone (0.788 vs. 0.743). CONCLUSIONS: The NCS provides more accurate predictions of the prognosis of GC patients, and its predictive value is significantly better than that of traditional inflammatory indicators or tumor markers. It is an effective complement to existing GC assessment systems.
format Online
Article
Text
id pubmed-9938584
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99385842023-02-19 Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer Yu, Liang Jiang, Runben Chen, Wanjing Liu, Yanwei Wang, Gui Gong, Xin Wang, Yong World J Surg Oncol Research BACKGROUND: Gastric cancer (GC) is one of the most common malignant tumors worldwide, and we hope to identify an economical but practical prognostic indicator. It has been reported that inflammatory indicators and tumor markers are associated with GC progression and are widely used to predict prognosis. However, existing prognostic models do not comprehensively analyze these predictors. METHODS: This study retrospectively reviewed 893 consecutive patients who underwent curative gastrectomy from January 1, 2012, to December 31, 2015, in the Second Hospital of Anhui Medical University. Prognostic factors predicting overall survival (OS) were analyzed using univariate and multivariate Cox regression analyses. Nomograms including independent prognostic factors were plotted for predicting survival. RESULTS: Ultimately, 425 patients were enrolled in this study. Multivariate analyses demonstrated that the neutrophil-to-lymphocyte ratio (NLR, total neutrophil count/lymphocyte count × 100%) and CA19-9 were independent prognostic factors for OS (p=0.001, p=0.016). The NLR-CA19-9 score (NCS) is constructed as the combination of the NLR and CA19-9. We defined NLR<2.46 and CA19-9≤37 U/ml as an NCS of 0, NLR≥2.46 or CA19-9>37 U/ml as an NCS 1, and NLR≥2.46 and CA19-9>37 U/ml as an NCS of 2. The results showed that higher NCS was significantly associated with worse clinicopathological characteristics and OS (p<0.05). Multivariate analyses revealed that the NCS was an independent prognostic factor for OS (NCS1: p<0.001, HR=3.172, 95% CI=2.120–4.745; NCS2: p<0.001, HR=3.052, 95% CI=1.928–4.832). Compared with traditional predictive indices, the NCS had the highest AUC for a 12-month survival, a 36-month survival, a 60-month survival, and OS (AUC= 0.654, 0.730, 0.811, 0.803, respectively). The nomogram had a higher Harrell’s C-index than the TNM stage alone (0.788 vs. 0.743). CONCLUSIONS: The NCS provides more accurate predictions of the prognosis of GC patients, and its predictive value is significantly better than that of traditional inflammatory indicators or tumor markers. It is an effective complement to existing GC assessment systems. BioMed Central 2023-02-18 /pmc/articles/PMC9938584/ /pubmed/36803398 http://dx.doi.org/10.1186/s12957-023-02926-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yu, Liang
Jiang, Runben
Chen, Wanjing
Liu, Yanwei
Wang, Gui
Gong, Xin
Wang, Yong
Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
title Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
title_full Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
title_fullStr Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
title_full_unstemmed Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
title_short Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
title_sort novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938584/
https://www.ncbi.nlm.nih.gov/pubmed/36803398
http://dx.doi.org/10.1186/s12957-023-02926-w
work_keys_str_mv AT yuliang novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer
AT jiangrunben novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer
AT chenwanjing novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer
AT liuyanwei novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer
AT wanggui novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer
AT gongxin novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer
AT wangyong novelprognosticindicatorcombininginflammatoryindicatorsandtumormarkersforgastriccancer